Use of IV Iron and Risk of Anaphylaxis: A Multinational Observational Post-Authorisation Safety Study in Europe

PURPOSE: This post-authorisation safety study estimated the risk of anaphylaxis in patients receiving intravenous (IV) iron in Europe, with interest in iron dextran and iron non-dextrans. Studies conducted in the United States have reported risk of anaphylaxis to IV iron ranging from 2.0 to 6.8 per...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacoepidemiology and drug safety 2021-06
Hauptverfasser: Fortuny, Joan, von Gersdorff, Gero, Lassalle, Regis, Linder, Marie, Overbeek, Jetty, Reinold, Jonas, Toft, Gunnar, Timmer, Antje, Dress, Jochen, Blin, Patrick, Droz-Perroteau, Cecile, Ehrenstein, Vera, Franzoni, Carla, Herings, Ron, Kollhorst, Bianca, Moore, Nicholas, Odsbu, Ingvild, Perez-Gutthann, Susana, Schink, Tania, Rascher, Katherine, Rasouliyan, Lawrence, Rothman, Kenneth J., Saigi-Morgui, Nuria, Schaller, Mathias, Smits, Elisabeth, Forstner, Michael, Benichou, Jacques, Bircher, Andreas J., Garbe, Edeltraut, Rampton, David S., Gutierrez, Lia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Pharmacoepidemiology and drug safety
container_volume
creator Fortuny, Joan
von Gersdorff, Gero
Lassalle, Regis
Linder, Marie
Overbeek, Jetty
Reinold, Jonas
Toft, Gunnar
Timmer, Antje
Dress, Jochen
Blin, Patrick
Droz-Perroteau, Cecile
Ehrenstein, Vera
Franzoni, Carla
Herings, Ron
Kollhorst, Bianca
Moore, Nicholas
Odsbu, Ingvild
Perez-Gutthann, Susana
Schink, Tania
Rascher, Katherine
Rasouliyan, Lawrence
Rothman, Kenneth J.
Saigi-Morgui, Nuria
Schaller, Mathias
Smits, Elisabeth
Forstner, Michael
Benichou, Jacques
Bircher, Andreas J.
Garbe, Edeltraut
Rampton, David S.
Gutierrez, Lia
description PURPOSE: This post-authorisation safety study estimated the risk of anaphylaxis in patients receiving intravenous (IV) iron in Europe, with interest in iron dextran and iron non-dextrans. Studies conducted in the United States have reported risk of anaphylaxis to IV iron ranging from 2.0 to 6.8 per 10 000 first treatments. METHODS: Cohort study of IV iron new users, captured mostly through pharmacy ambulatory dispensing, from populations covered by health and administrative data sources in five European countries from 1999 to 2017. Anaphylaxis events were identified through an algorithm that used parenteral penicillin as a positive control. RESULTS: A total of 304 210 patients with a first IV iron treatment (6367 iron dextran), among whom 13–16 anaphylaxis cases were identified and reported as a range to comply with data protection regulations. The pooled unadjusted incidence proportion (IP) ranged from 0.4 (95% confidence interval [CI], 0.2–0.9) to 0.5 (95% CI, 0.3–1.0) per 10 000 first treatments. No events were identified at first dextran treatments. There were 231 294 first penicillin treatments with 30 potential cases of anaphylaxis (IP = 1.2; 95% CI, 0.8–1.7 per 10 000 treatments). CONCLUSION: We found an IP of anaphylaxis from 0.4 to 0.5 per 10 000 first IV iron treatments. The study captured only a fraction of IV iron treatments administered in hospitals, where most first treatments are likely to happen. Due to this limitation, the study could not exclude a differential risk of anaphylaxis between iron dextran and iron non-dextrans. The IP of anaphylaxis in users of penicillin was consistent with incidences reported in the literature.
doi_str_mv 10.1002/pds.5319
format Article
fullrecord <record><control><sourceid>hal</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03287566v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_HAL_hal_03287566v1</sourcerecordid><originalsourceid>FETCH-hal_primary_oai_HAL_hal_03287566v13</originalsourceid><addsrcrecordid>eNqVilFPwjAUhRuDiYAm_oT76sOwZXZQ3xaDgUQCAfV1uWZdVint0tsR9-91Rn8AT-c73zmM3Qo-EZxP75uSJjIV6oINBVcqEVLOBj3LNJnLTF2xEdEn5z-behgy_0YafAWrd1gF7wBdCTtDh97lDpu6s_hl6BFyWLc2GofReIcWNh-kw-m_bT3FJG9j7YOhXwl7rHTsYB_bsgPjYNEG3-hrdlmhJX3zl2N297x4fVomNdqiCeaIoSs8mmKZvxS94-l0PpNZdhLpOd9vugJS0w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Use of IV Iron and Risk of Anaphylaxis: A Multinational Observational Post-Authorisation Safety Study in Europe</title><source>Wiley-Blackwell Journals</source><creator>Fortuny, Joan ; von Gersdorff, Gero ; Lassalle, Regis ; Linder, Marie ; Overbeek, Jetty ; Reinold, Jonas ; Toft, Gunnar ; Timmer, Antje ; Dress, Jochen ; Blin, Patrick ; Droz-Perroteau, Cecile ; Ehrenstein, Vera ; Franzoni, Carla ; Herings, Ron ; Kollhorst, Bianca ; Moore, Nicholas ; Odsbu, Ingvild ; Perez-Gutthann, Susana ; Schink, Tania ; Rascher, Katherine ; Rasouliyan, Lawrence ; Rothman, Kenneth J. ; Saigi-Morgui, Nuria ; Schaller, Mathias ; Smits, Elisabeth ; Forstner, Michael ; Benichou, Jacques ; Bircher, Andreas J. ; Garbe, Edeltraut ; Rampton, David S. ; Gutierrez, Lia</creator><creatorcontrib>Fortuny, Joan ; von Gersdorff, Gero ; Lassalle, Regis ; Linder, Marie ; Overbeek, Jetty ; Reinold, Jonas ; Toft, Gunnar ; Timmer, Antje ; Dress, Jochen ; Blin, Patrick ; Droz-Perroteau, Cecile ; Ehrenstein, Vera ; Franzoni, Carla ; Herings, Ron ; Kollhorst, Bianca ; Moore, Nicholas ; Odsbu, Ingvild ; Perez-Gutthann, Susana ; Schink, Tania ; Rascher, Katherine ; Rasouliyan, Lawrence ; Rothman, Kenneth J. ; Saigi-Morgui, Nuria ; Schaller, Mathias ; Smits, Elisabeth ; Forstner, Michael ; Benichou, Jacques ; Bircher, Andreas J. ; Garbe, Edeltraut ; Rampton, David S. ; Gutierrez, Lia</creatorcontrib><description>PURPOSE: This post-authorisation safety study estimated the risk of anaphylaxis in patients receiving intravenous (IV) iron in Europe, with interest in iron dextran and iron non-dextrans. Studies conducted in the United States have reported risk of anaphylaxis to IV iron ranging from 2.0 to 6.8 per 10 000 first treatments. METHODS: Cohort study of IV iron new users, captured mostly through pharmacy ambulatory dispensing, from populations covered by health and administrative data sources in five European countries from 1999 to 2017. Anaphylaxis events were identified through an algorithm that used parenteral penicillin as a positive control. RESULTS: A total of 304 210 patients with a first IV iron treatment (6367 iron dextran), among whom 13–16 anaphylaxis cases were identified and reported as a range to comply with data protection regulations. The pooled unadjusted incidence proportion (IP) ranged from 0.4 (95% confidence interval [CI], 0.2–0.9) to 0.5 (95% CI, 0.3–1.0) per 10 000 first treatments. No events were identified at first dextran treatments. There were 231 294 first penicillin treatments with 30 potential cases of anaphylaxis (IP = 1.2; 95% CI, 0.8–1.7 per 10 000 treatments). CONCLUSION: We found an IP of anaphylaxis from 0.4 to 0.5 per 10 000 first IV iron treatments. The study captured only a fraction of IV iron treatments administered in hospitals, where most first treatments are likely to happen. Due to this limitation, the study could not exclude a differential risk of anaphylaxis between iron dextran and iron non-dextrans. The IP of anaphylaxis in users of penicillin was consistent with incidences reported in the literature.</description><identifier>ISSN: 1053-8569</identifier><identifier>EISSN: 1099-1557</identifier><identifier>DOI: 10.1002/pds.5319</identifier><language>eng</language><publisher>Wiley</publisher><subject>Life Sciences ; Santé publique et épidémiologie</subject><ispartof>Pharmacoepidemiology and drug safety, 2021-06</ispartof><rights>Attribution - NonCommercial - NoDerivatives</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://hal.science/hal-03287566$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Fortuny, Joan</creatorcontrib><creatorcontrib>von Gersdorff, Gero</creatorcontrib><creatorcontrib>Lassalle, Regis</creatorcontrib><creatorcontrib>Linder, Marie</creatorcontrib><creatorcontrib>Overbeek, Jetty</creatorcontrib><creatorcontrib>Reinold, Jonas</creatorcontrib><creatorcontrib>Toft, Gunnar</creatorcontrib><creatorcontrib>Timmer, Antje</creatorcontrib><creatorcontrib>Dress, Jochen</creatorcontrib><creatorcontrib>Blin, Patrick</creatorcontrib><creatorcontrib>Droz-Perroteau, Cecile</creatorcontrib><creatorcontrib>Ehrenstein, Vera</creatorcontrib><creatorcontrib>Franzoni, Carla</creatorcontrib><creatorcontrib>Herings, Ron</creatorcontrib><creatorcontrib>Kollhorst, Bianca</creatorcontrib><creatorcontrib>Moore, Nicholas</creatorcontrib><creatorcontrib>Odsbu, Ingvild</creatorcontrib><creatorcontrib>Perez-Gutthann, Susana</creatorcontrib><creatorcontrib>Schink, Tania</creatorcontrib><creatorcontrib>Rascher, Katherine</creatorcontrib><creatorcontrib>Rasouliyan, Lawrence</creatorcontrib><creatorcontrib>Rothman, Kenneth J.</creatorcontrib><creatorcontrib>Saigi-Morgui, Nuria</creatorcontrib><creatorcontrib>Schaller, Mathias</creatorcontrib><creatorcontrib>Smits, Elisabeth</creatorcontrib><creatorcontrib>Forstner, Michael</creatorcontrib><creatorcontrib>Benichou, Jacques</creatorcontrib><creatorcontrib>Bircher, Andreas J.</creatorcontrib><creatorcontrib>Garbe, Edeltraut</creatorcontrib><creatorcontrib>Rampton, David S.</creatorcontrib><creatorcontrib>Gutierrez, Lia</creatorcontrib><title>Use of IV Iron and Risk of Anaphylaxis: A Multinational Observational Post-Authorisation Safety Study in Europe</title><title>Pharmacoepidemiology and drug safety</title><description>PURPOSE: This post-authorisation safety study estimated the risk of anaphylaxis in patients receiving intravenous (IV) iron in Europe, with interest in iron dextran and iron non-dextrans. Studies conducted in the United States have reported risk of anaphylaxis to IV iron ranging from 2.0 to 6.8 per 10 000 first treatments. METHODS: Cohort study of IV iron new users, captured mostly through pharmacy ambulatory dispensing, from populations covered by health and administrative data sources in five European countries from 1999 to 2017. Anaphylaxis events were identified through an algorithm that used parenteral penicillin as a positive control. RESULTS: A total of 304 210 patients with a first IV iron treatment (6367 iron dextran), among whom 13–16 anaphylaxis cases were identified and reported as a range to comply with data protection regulations. The pooled unadjusted incidence proportion (IP) ranged from 0.4 (95% confidence interval [CI], 0.2–0.9) to 0.5 (95% CI, 0.3–1.0) per 10 000 first treatments. No events were identified at first dextran treatments. There were 231 294 first penicillin treatments with 30 potential cases of anaphylaxis (IP = 1.2; 95% CI, 0.8–1.7 per 10 000 treatments). CONCLUSION: We found an IP of anaphylaxis from 0.4 to 0.5 per 10 000 first IV iron treatments. The study captured only a fraction of IV iron treatments administered in hospitals, where most first treatments are likely to happen. Due to this limitation, the study could not exclude a differential risk of anaphylaxis between iron dextran and iron non-dextrans. The IP of anaphylaxis in users of penicillin was consistent with incidences reported in the literature.</description><subject>Life Sciences</subject><subject>Santé publique et épidémiologie</subject><issn>1053-8569</issn><issn>1099-1557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqVilFPwjAUhRuDiYAm_oT76sOwZXZQ3xaDgUQCAfV1uWZdVint0tsR9-91Rn8AT-c73zmM3Qo-EZxP75uSJjIV6oINBVcqEVLOBj3LNJnLTF2xEdEn5z-behgy_0YafAWrd1gF7wBdCTtDh97lDpu6s_hl6BFyWLc2GofReIcWNh-kw-m_bT3FJG9j7YOhXwl7rHTsYB_bsgPjYNEG3-hrdlmhJX3zl2N297x4fVomNdqiCeaIoSs8mmKZvxS94-l0PpNZdhLpOd9vugJS0w</recordid><startdate>20210628</startdate><enddate>20210628</enddate><creator>Fortuny, Joan</creator><creator>von Gersdorff, Gero</creator><creator>Lassalle, Regis</creator><creator>Linder, Marie</creator><creator>Overbeek, Jetty</creator><creator>Reinold, Jonas</creator><creator>Toft, Gunnar</creator><creator>Timmer, Antje</creator><creator>Dress, Jochen</creator><creator>Blin, Patrick</creator><creator>Droz-Perroteau, Cecile</creator><creator>Ehrenstein, Vera</creator><creator>Franzoni, Carla</creator><creator>Herings, Ron</creator><creator>Kollhorst, Bianca</creator><creator>Moore, Nicholas</creator><creator>Odsbu, Ingvild</creator><creator>Perez-Gutthann, Susana</creator><creator>Schink, Tania</creator><creator>Rascher, Katherine</creator><creator>Rasouliyan, Lawrence</creator><creator>Rothman, Kenneth J.</creator><creator>Saigi-Morgui, Nuria</creator><creator>Schaller, Mathias</creator><creator>Smits, Elisabeth</creator><creator>Forstner, Michael</creator><creator>Benichou, Jacques</creator><creator>Bircher, Andreas J.</creator><creator>Garbe, Edeltraut</creator><creator>Rampton, David S.</creator><creator>Gutierrez, Lia</creator><general>Wiley</general><scope>1XC</scope><scope>VOOES</scope></search><sort><creationdate>20210628</creationdate><title>Use of IV Iron and Risk of Anaphylaxis: A Multinational Observational Post-Authorisation Safety Study in Europe</title><author>Fortuny, Joan ; von Gersdorff, Gero ; Lassalle, Regis ; Linder, Marie ; Overbeek, Jetty ; Reinold, Jonas ; Toft, Gunnar ; Timmer, Antje ; Dress, Jochen ; Blin, Patrick ; Droz-Perroteau, Cecile ; Ehrenstein, Vera ; Franzoni, Carla ; Herings, Ron ; Kollhorst, Bianca ; Moore, Nicholas ; Odsbu, Ingvild ; Perez-Gutthann, Susana ; Schink, Tania ; Rascher, Katherine ; Rasouliyan, Lawrence ; Rothman, Kenneth J. ; Saigi-Morgui, Nuria ; Schaller, Mathias ; Smits, Elisabeth ; Forstner, Michael ; Benichou, Jacques ; Bircher, Andreas J. ; Garbe, Edeltraut ; Rampton, David S. ; Gutierrez, Lia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-hal_primary_oai_HAL_hal_03287566v13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Life Sciences</topic><topic>Santé publique et épidémiologie</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fortuny, Joan</creatorcontrib><creatorcontrib>von Gersdorff, Gero</creatorcontrib><creatorcontrib>Lassalle, Regis</creatorcontrib><creatorcontrib>Linder, Marie</creatorcontrib><creatorcontrib>Overbeek, Jetty</creatorcontrib><creatorcontrib>Reinold, Jonas</creatorcontrib><creatorcontrib>Toft, Gunnar</creatorcontrib><creatorcontrib>Timmer, Antje</creatorcontrib><creatorcontrib>Dress, Jochen</creatorcontrib><creatorcontrib>Blin, Patrick</creatorcontrib><creatorcontrib>Droz-Perroteau, Cecile</creatorcontrib><creatorcontrib>Ehrenstein, Vera</creatorcontrib><creatorcontrib>Franzoni, Carla</creatorcontrib><creatorcontrib>Herings, Ron</creatorcontrib><creatorcontrib>Kollhorst, Bianca</creatorcontrib><creatorcontrib>Moore, Nicholas</creatorcontrib><creatorcontrib>Odsbu, Ingvild</creatorcontrib><creatorcontrib>Perez-Gutthann, Susana</creatorcontrib><creatorcontrib>Schink, Tania</creatorcontrib><creatorcontrib>Rascher, Katherine</creatorcontrib><creatorcontrib>Rasouliyan, Lawrence</creatorcontrib><creatorcontrib>Rothman, Kenneth J.</creatorcontrib><creatorcontrib>Saigi-Morgui, Nuria</creatorcontrib><creatorcontrib>Schaller, Mathias</creatorcontrib><creatorcontrib>Smits, Elisabeth</creatorcontrib><creatorcontrib>Forstner, Michael</creatorcontrib><creatorcontrib>Benichou, Jacques</creatorcontrib><creatorcontrib>Bircher, Andreas J.</creatorcontrib><creatorcontrib>Garbe, Edeltraut</creatorcontrib><creatorcontrib>Rampton, David S.</creatorcontrib><creatorcontrib>Gutierrez, Lia</creatorcontrib><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Pharmacoepidemiology and drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fortuny, Joan</au><au>von Gersdorff, Gero</au><au>Lassalle, Regis</au><au>Linder, Marie</au><au>Overbeek, Jetty</au><au>Reinold, Jonas</au><au>Toft, Gunnar</au><au>Timmer, Antje</au><au>Dress, Jochen</au><au>Blin, Patrick</au><au>Droz-Perroteau, Cecile</au><au>Ehrenstein, Vera</au><au>Franzoni, Carla</au><au>Herings, Ron</au><au>Kollhorst, Bianca</au><au>Moore, Nicholas</au><au>Odsbu, Ingvild</au><au>Perez-Gutthann, Susana</au><au>Schink, Tania</au><au>Rascher, Katherine</au><au>Rasouliyan, Lawrence</au><au>Rothman, Kenneth J.</au><au>Saigi-Morgui, Nuria</au><au>Schaller, Mathias</au><au>Smits, Elisabeth</au><au>Forstner, Michael</au><au>Benichou, Jacques</au><au>Bircher, Andreas J.</au><au>Garbe, Edeltraut</au><au>Rampton, David S.</au><au>Gutierrez, Lia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of IV Iron and Risk of Anaphylaxis: A Multinational Observational Post-Authorisation Safety Study in Europe</atitle><jtitle>Pharmacoepidemiology and drug safety</jtitle><date>2021-06-28</date><risdate>2021</risdate><issn>1053-8569</issn><eissn>1099-1557</eissn><abstract>PURPOSE: This post-authorisation safety study estimated the risk of anaphylaxis in patients receiving intravenous (IV) iron in Europe, with interest in iron dextran and iron non-dextrans. Studies conducted in the United States have reported risk of anaphylaxis to IV iron ranging from 2.0 to 6.8 per 10 000 first treatments. METHODS: Cohort study of IV iron new users, captured mostly through pharmacy ambulatory dispensing, from populations covered by health and administrative data sources in five European countries from 1999 to 2017. Anaphylaxis events were identified through an algorithm that used parenteral penicillin as a positive control. RESULTS: A total of 304 210 patients with a first IV iron treatment (6367 iron dextran), among whom 13–16 anaphylaxis cases were identified and reported as a range to comply with data protection regulations. The pooled unadjusted incidence proportion (IP) ranged from 0.4 (95% confidence interval [CI], 0.2–0.9) to 0.5 (95% CI, 0.3–1.0) per 10 000 first treatments. No events were identified at first dextran treatments. There were 231 294 first penicillin treatments with 30 potential cases of anaphylaxis (IP = 1.2; 95% CI, 0.8–1.7 per 10 000 treatments). CONCLUSION: We found an IP of anaphylaxis from 0.4 to 0.5 per 10 000 first IV iron treatments. The study captured only a fraction of IV iron treatments administered in hospitals, where most first treatments are likely to happen. Due to this limitation, the study could not exclude a differential risk of anaphylaxis between iron dextran and iron non-dextrans. The IP of anaphylaxis in users of penicillin was consistent with incidences reported in the literature.</abstract><pub>Wiley</pub><doi>10.1002/pds.5319</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1053-8569
ispartof Pharmacoepidemiology and drug safety, 2021-06
issn 1053-8569
1099-1557
language eng
recordid cdi_hal_primary_oai_HAL_hal_03287566v1
source Wiley-Blackwell Journals
subjects Life Sciences
Santé publique et épidémiologie
title Use of IV Iron and Risk of Anaphylaxis: A Multinational Observational Post-Authorisation Safety Study in Europe
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T14%3A38%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-hal&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20IV%20Iron%20and%20Risk%20of%20Anaphylaxis:%20A%20Multinational%20Observational%20Post-Authorisation%20Safety%20Study%20in%20Europe&rft.jtitle=Pharmacoepidemiology%20and%20drug%20safety&rft.au=Fortuny,%20Joan&rft.date=2021-06-28&rft.issn=1053-8569&rft.eissn=1099-1557&rft_id=info:doi/10.1002/pds.5319&rft_dat=%3Chal%3Eoai_HAL_hal_03287566v1%3C/hal%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true